FDA Grants Accelerated Approval for OTOF Gene Therapy - Top-Institutions - MDSpire

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

  • By

  • Kathryn Wighton

  • April 23, 2026

  • 3 min

Share

Top Institutions in Otolaryngology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts Eye and Ear Infirmary
    Massachusetts Eye and Ear Infirmary

    Boston, MA

    Key Differentiators

    • Otolaryngology
    • Audiology
    • Gene Therapy
    • Neurotology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Otolaryngology
    • Genetics
    • Gene Therapy
    • Audiology

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Otolaryngology
    • Gene Therapy
    • Audiology
    • Neuroscience

  • #4

    The Hospital for Sick Children (SickKids)
    The Hospital for Sick Children (SickKids)

    Toronto, ON

    Key Differentiators

    • Pediatric Otolaryngology
    • Genetics
    • Gene Therapy

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Gene Therapy
    • Otolaryngology
    • Audiology
    • Neuroscience

Original Source(s)

FDA Grants Accelerated Approval for OTOF Gene Therapy

  • by Kathryn Wighton

  • April 23, 2026

Related Content

A Smarter Screen for Sleep Apnea Stimulation

A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation

Reduced-Dose Radiation Shows Durable Control

Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies